ReFacto AF
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hemophilia A
Conditions
Hemophilia A
Trial Timeline
Apr 1, 2006 → Jun 1, 2008
NCT ID
NCT00243659About ReFacto AF
ReFacto AF is a phase 3 stage product being developed by Pfizer for Hemophilia A. The current trial status is completed. This product is registered under clinical trial identifier NCT00243659. Target conditions include Hemophilia A.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00038935 | Phase 3 | Completed |
| NCT00037544 | Phase 3 | Completed |
| NCT02718677 | Pre-clinical | Withdrawn |
| NCT00243659 | Phase 3 | Completed |
Competing Products
20 competing products in Hemophilia A
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 77 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Roche | Phase 3 | 77 |
| HEMLIBRA | Johnson & Johnson | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Emicizumab | Roche | Approved | 85 |
| Emicizumab | Roche | Phase 3 | 77 |
| SPK-8011QQ | Roche | Phase 1/2 | 41 |
| NXT007 | Roche | Phase 1/2 | 41 |
| Emicizumab Injection | Roche | Phase 2 | 52 |
| Bypassing Agents + FVIII Replacement | Roche | Pre-clinical | 23 |
| PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 | Pfizer | Phase 2 | 51 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 22 |
| Refacto AF | Pfizer | Pre-clinical | 22 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 76 |
| Nonacog alfa + Nonacog alfa | Pfizer | Phase 3 | 76 |